The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that...
Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the ...
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precis...
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic h...
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic h...
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and prec...
Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regio...
FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and prec...
Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United ...